This paper replicates DiMasi et al (2003 DiMasi et al ( , 2004 estimates of expenditure on new drug development using publicly available data. The paper estimates that average expenditure on drugs in human clinical trials is around $25m per year, with $18m per year on drugs in Phase 1, $33m on drugs in Phase 2 and $19m per year on drugs in Phase 3 of the human clinical trials. The paper's estimated expenditure on new drug development is somewhat greater than suggested by the survey results presented in DiMasi et al (2003, 2004). The paper combines a twelve year panel of research and development expenditure for 183 publicly traded firms in the pharmaceutical industry with panel of drugs in human clinical trials for each firm over the same period. The paper estimates drug expenditure by estimating the relationship between research and development expenditure and the number of drugs in development for 1,682 company/years (183 firms multiplied by the number of years for which we have financial and drug development information). The paper also estimates expenditure on drugs in various therapeutic categories. The paper confirms earlier work by the authors that $802m may under estimate the average amount needed to bring a new molecular entity to market. It also confirms that there is significant variation in spending by therapeutic category.
Introduction
estimate the cost of new drug development for all drugs and for drugs in certain therapeutic categories, respectively. The authors estimate the average cost of new drug development to be $802m per new drug. This number has become a central part of the policy debates on numerous policy issues regarding the pharmaceutical industry including the Medicare Prescription Drug Act, drug importation, generic entry and vaccine development. Drug companies argue the high cost of drug development justifies the high prices paid by governments, insurers and customers. Given the importance of the $802m number to the debate it is important to know whether it is correct and what it means. DiMasi et al (2003) calculate the cost of new drug development with data from two sources. The authors survey ten large pharmaceutical firms and ask those firms to report the expenditure in human clinical trials for 68 drugs chosen at random from the Tuft's drug development database called the CSDD. The authors then use information on average success rates and successful durations from the CSDD data to calculate the cost of bringing a new drug to market. Recently, Light and Warburton (2005) point out numerous problems with DiMasi et al (2003) . In particular, because "cost data used was proprietary and confidential, readers cannot know how each company collected its data, or what was counted as research costs, and no independent verification of the accuracy of the information is possible" (p. 1031). This paper provides an independent verification of the survey cost data by using an alternative publicly available data source on research and development expenditure. In a companion paper, Adams and Brantner (2006) verify the second part of DiMasi et al (2003) paper by using publicly available data to estimate success rates and average successful durations.
By comparing aggregate annual expenditure on research and development across firms and over time to the number of drugs in human clinical trials for each firm and each year, we can determine the "marginal expenditure" on an additional drug in development. If Drug Firm A spends an additional $50m in 1992 relative to 1991 but in 1992 Drug Firm A has two additional drugs in development we argue this provides an estimate of average annual expenditure by Drug Firm A, i.e. $25m per drug per year. Similarly, if Drug Firm B spends $100m more than Drug Firm A in 1992 but Drug Firm B has an additional four drugs in development in 1992, then we estimate drug expenditure to be $25m per drug per year. Note that this is an estimate of the correlation between expenditure and the number of drugs in development. We are not attempting to estimate the impact of an additional dollar of expenditure on the number of drugs in development or the impact of additional drug on the amount of expenditure.
There are a number of advantages to this approach. First, we are using publicly available data so our results can be verified by other researchers. Second, we are using data from 183 publicly traded firms rather than ten firms selected by the study's authors. Our selection criteria is that the firms have research and development expenditure information in the CompuStat data base, be in the pharmaceutical industry (see Danzon et al (2004) ) and have drugs in the Pharmaprojects data set (see Adams and Brantner (2006) ). These firms range in size from 100 employees to almost 180,000 employees with sales ranging from $2m annually to almost $45b annually. Third, we are using contemporaneous reports of research and development expenditure where the reports are scrutinized by both the market and the SEC. In their comment on DiMasi et al (2003) , Light and Warburton (2005) argue that considering the clear interest of pharmaceutical companies in higher (rather than lower) estimates of drug development costs, and sampled firms' likely awareness of the intended use of the survey data, it is not unlikely that companies would deliberately and systematically overstate costs in their survey responses. (p. 1031)
We argue that such biases are less likely here given the large number of firms and the checks on the reports including audits.
Of course there are also serious concerns about the approach we use here. First, the data is aggregate research and development expenditure. It not only includes expenditure on drugs in human clinical trials it also includes development expenditure on drugs yet to reach trials. To identify the amount spent in human clinical trials we must infer the information from cross sectional and time-series variation in expenditure that is associated with variation in the number of drugs in development. Such variation may lead to spurious estimates. For example, if one firm specializes in cancer drugs and we compare the specialty firm's expenditure on cancer drugs to that of a firm that has just one or two cancer drugs, we may estimate that expenditure on the extra drug is negative -a theoretical impossibility. We attempt to control for some cross sectional variation between firms by conditioning on net sales. Second, we are estimating changes for the "marginal drug" which may be more expensive than the average drug. with these approaches is that less than one in four drugs in human clinical trials actually make it to the market and the process can take between six and twelve years with substantial variation across drugs (Adams and Brantner (2003) ).
The rest of the paper proceeds as follows. Section 2 discusses the data used in this study and provides some background information on new drug development. Section 3 presents the results. Section 4 concludes.
Data and Background
This paper combines data from two data sources. Information on each firm's research and development expenditure comes from the Standard Poor's CompuStat Industrial file and Global Vantage Industrial Commercial file used by Danzon et al (2004) . Pharmaprojects updates its information on the firms developing each drug after a merger, so
we used text searches of the database and searches of a related data set called the Manufacturing Index to determine the ownership of drugs over time.
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According to Danzon et al (2004) Table 4 presents results from the 25%, 50% and 75% quantile regressions.
Results

Mean Expenditure Estimates
Comparing these results to the results from columns 5 and 6 in Table 3 we see that expenditure per drug per year is substantially less at the lower quantiles. At the bottom quartile expenditure per new drug in development is around $8m per year, with $13m at the median and $16m at the top quartile. These numbers compare to $25m per year for the mean. Similarly, estimated expenditures per phase of development are substantially lower at the 25%, 50% and 75% quantiles relative to the mean.
As before, we can transform our median estimates to compare to the median estimates presented in DiMasi et al (2003) . This procedure gives 1.25*14.13m = $17.66m
for Phase 1, which is more than DiMasi et al (2003) estimate of $13.9m for Phase 1. For Phase 2 the same method produces an estimate of $39.9m which is much higher than the DiMasi et al (2003) estimate of $17m. Finally, for Phase 3 this method gives an estimate of $24.4m which is much less than the DiMasi et al (2003) estimate of $62m.
Implications for Cost Estimates
If we use the mean estimates for expenditure on drugs in development in place of the survey estimates used by DiMasi et al (2003) we can recalculate the over all "cost of drug development" or more accurately the net revenue needed to make investment in drug development profitable. Doing this calculation using the same durations and success rates as reported in Adams and Brantner (2006) we estimate new drug development cost to be $1,176m, which is much higher than the original estimate of $802m or even the Adams and
Brantner (2006) estimate of $867m. If we use the durations and success rates reported in Table 2 then the estimate falls to $1,057m, but still higher than previous estimates. These high estimates may be due to measurement of expenditure on the marginal drug rather than the average drug. However, such an estimate may be more useful to policy makers as it is more likely to measure the impact of changes in policy on the development of new drugs.
We could interpret these estimates as stating a firm would need expected net revenue of over $1 billion to develop one more drug for the market. 
Expenditure By Therapy
DiMasi et al (2004) presents estimates of drug development costs for a small number of major therapies. In attempt to replicate this work, Table 4 presents results similar to those presented in Table 3 but where the drug counts are by major therapeutic category. One difference between the results reported here and the expenditure by therapeutic category reported in DiMasi et al (2004) is in relation to anti-infectives such as penicillin.
According to DiMasi et al (2004) the expenditure in Phase 3 on these drugs is $137m while Phase 1 expenditure is $23m and Phase 2 expenditure is $20m. Here we find that average expenditure on anti-infectives is less than for the average drug, and this also holds true for expenditure by phase (not reported). Note however, that our estimate for expenditure on this drug falls dramatically when we account for sales across firms, suggesting that larger firms are spending more per drug on developing anti-infectives.
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In relation to cardiovascular drugs DiMasi et al (2004) suggests expenditure is slightly below average, our estimate puts expenditure on these drugs at slightly above average although the standard error includes the average.
These results support the argument in Adams and Brantner (2006) 
Conclusion
Recent criticism of the study by DiMasi et al (2003) and durations from Adams and Brantner (2006) we find that the "cost of drug development"
(or the net revenue needed to make investment in new drugs profitable) is over $1 billion and higher than the DiMasi et al (2003) estimate of $802m. As we are estimating expenditure on the additional drug we may be estimating the revenue needed to invest in the marginal rather than the average drug. While this is likely to make our estimate higher, it may also make our estimate more useful when considering the consequences of policy changes such as price regulation. This paper also confirms results presented in Adams and Brantner (2006) that there is a substantial amount of variation in expenditure by therapeutic category. 
